Effect of dialysis dose and membrane flux in maintenance hemodialysis.

被引:1416
作者
Eknoyan, G
Beck, GJ
Cheung, AK
Daugirdas, JT
Greene, T
Kusek, JW
Allon, M
Bailey, J
Delmez, JA
Depner, TA
Dwyer, JT
Levey, AS
Levin, NW
Milford, E
Ornt, DB
Rocco, MV
Schulman, G
Schwab, SJ
Teehan, BP
Toto, R
机构
[1] Cleveland Clin Fdn, Dept Biostat & Epidemiol, HEMO Data Coordinating Ctr, Cleveland, OH 44195 USA
[2] Baylor Coll Med, Houston, TX 77030 USA
[3] Univ Utah, Salt Lake City, UT USA
[4] Vet Affairs Salt Lake City Hlth Care Syst, Salt Lake City, UT USA
[5] Univ Illinois, Chicago, IL USA
[6] Vet Affairs Chicago Hlth Care Syst, Chicago, IL USA
[7] NIDDKD, Bethesda, MD 20892 USA
[8] Univ Alabama Birmingham, Birmingham, AL USA
[9] Emory Univ Hosp, Atlanta, GA 30322 USA
[10] Washington Univ, St Louis, MO USA
[11] Univ Calif Davis, Sacramento, CA 95817 USA
[12] Tufts Univ New England Med Ctr, Boston, MA 02111 USA
[13] Beth Israel Deaconess Med Ctr, New York, NY 10003 USA
[14] Brigham & Womens Hosp, Boston, MA 02115 USA
[15] Univ Rochester, Rochester, NY USA
[16] Wake Forest Univ, Winston Salem, NC 27109 USA
[17] Vanderbilt Univ, Nashville, TN USA
[18] Duke Univ, Durham, NC USA
[19] Lankenau Hosp & Med Res Ctr, Wynnewood, PA USA
[20] Univ Texas, SW Med Ctr, Dallas, TX USA
关键词
D O I
10.1056/NEJMoa021583
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The effects of the dose of dialysis and the level of flux of the dialyzer membrane on mortality and morbidity among patients undergoing maintenance hemodialysis are uncertain. Methods: We undertook a randomized clinical trial in 1846 patients undergoing thrice-weekly dialysis, using a two-by-two factorial design to assign patients randomly to a standard or high dose of dialysis and to a low-flux or high-flux dialyzer. Results: In the standard-dose group, the mean (+/-SD) urea-reduction ratio was 66.3+/-2.5 percent, the single-pool Kt/V was 1.32+/-0.09, and the equilibrated Kt/V was 1.16+/-0.08; in the high-dose group, the values were 75.2+/-2.5 percent, 1.71+/-0.11, and 1.53+/-0.09, respectively. Flux, estimated on the basis of beta(sub 2)-microglobulin clearance, was 3+/-7 ml per minute in the low-flux group and 34+/-11 ml per minute in the high-flux group. The primary outcome, death from any cause, was not significantly influenced by the dose or flux assignment: the relative risk of death in the high-dose group as compared with the standard-dose group was 0.96 (95 percent confidence interval, 0.84 to 1.10; P=0.53), and the relative risk of death in the high-flux group as compared with the low-flux group was 0.92 (95 percent confidence interval, 0.81 to 1.05; P=0.23). The main secondary outcomes (first hospitalization for cardiac causes or death from any cause, first hospitalization for infection or death from any cause, first 15 percent decrease in the serum albumin level or death from any cause, and all hospitalizations not related to vascular access) also did not differ significantly between either the dose groups or the flux groups. Possible benefits of the dose or flux interventions were suggested in two of seven prespecified subgroups of patients. Conclusions: Patients undergoing hemodialysis thrice weekly appear to have no major benefit from a higher dialysis dose than that recommended by current U.S. guidelines or from the use of a high-flux membrane.
引用
收藏
页码:2010 / 2019
页数:10
相关论文
共 38 条
  • [1] Cheung AK, 1999, J AM SOC NEPHROL, V10, P117
  • [2] COLLINS A, 1994, AM J KIDNEY DIS, V24, P157
  • [3] COX DR, 1972, J R STAT SOC B, V34, P187
  • [4] DAUGIRDAS JT, 1995, ASAIO J, V41, pM719, DOI 10.1097/00002480-199507000-00107
  • [5] Depner TA., 1991, PRESCRIBING HEMODIAL
  • [6] The dangers of inferring treatment effects from observational data: a case study in HIV infection
    Dunn, D
    Babiker, A
    Hooker, M
    Darbyshire, J
    [J]. CONTROLLED CLINICAL TRIALS, 2002, 23 (02): : 106 - 110
  • [7] Eknoyan G, 1997, KIDNEY INT, V52, P1395
  • [8] The hemodialysis (HEMO) study: Rationale for selection of interventions
    Eknoyan, G
    Levey, AS
    Beck, GJ
    Agodoa, LY
    Daugirdas, JT
    Kusek, JW
    Levin, NW
    Schulman, G
    [J]. SEMINARS IN DIALYSIS, 1996, 9 (01) : 24 - 33
  • [9] Continuous quality improvement: DOQI becomes K/DOQI and is updated
    Eknoyan, G
    Levin, NW
    Eschbach, JW
    Golper, TA
    Owen, WF
    Schwab, S
    Steinberg, EP
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 37 (01) : 179 - 180
  • [10] Untitled - Foreword
    Eknoyan, G
    Levin, N
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 37 (01) : S5 - S6